Skip to main content

Advertisement

SpringerLink
Log in

Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression

  • Regular Article
  • Published:
Cell and Tissue Research Aims and scope Submit manuscript

Abstract

Fibroblast growth factor 2 (FGF2), produced as high (Hi-) and low (Lo-) molecular weight isoforms, is implicated in cardiac response to injury. The role of endogenous FGF2 isoforms during chronic stress is not well defined. We investigated the effects of endogenous Hi-FGF2 in a mouse model of simulated pressure-overload stress achieved by transverse aortic constriction (TAC) surgery. Hi-FGF2 knockout mice, expressing only Lo-FGF2, FGF2(Lo), and wild-type mice, FGF2(WT), expressing both Hi-FGF2 and Lo-FGF2, were used. By echocardiography, a decline in systolic function was observed in FGF2(WT) but not FGF2(Lo) mice compared to corresponding sham-operated animals at 4–8 weeks post-TAC surgery. TAC surgery increased markers of myocardial stress/damage including B-type natriuretic peptide (BNP) and the pro-cell death protein BCL2/adenovirus E1B 19 kDa protein-interacting protein-3 (Bnip3) in FGF2(WT) but not FGF2(Lo) mice. In FGF2(Lo) mice, cardiac levels of activated FGF receptor 1 (FGFR1), and downstream signals, including phosphorylated mTOR and p70S6 kinase, were elevated post-TAC. Finally, NR1D1 (nuclear receptor subfamily 1 group D member 1), implicated in cardioprotection from pressure-overload stress, was downregulated or upregulated in the presence or absence, respectively, of Hi-FGF2 expression, post-TAC surgery. In wild-type cardiomyocyte cultures, endothelin-1 (added to simulate pressure-overload signals) caused NR1D1 downregulation and BNP upregulation, similar to the effect of TAC surgery on the FGF2(WT) mice. The NR1D1 agonist SR9009 prevented BNP upregulation, simulating post-TAC findings in FGF2(Lo) mice. We propose that elimination of Hi-FGF2 is cardioprotective during pressure-overload by increasing FGFR1-associated signaling and NR1D1 expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Azhar M, Yin M, Zhou M, Li H, Mustafa M, Nusayr E, Keenan JB, Chen H, Pawlosky S, Gard C, Grisham C, Sanford LP, Doetschman T (2009) Gene targeted ablation of high molecular weight fibroblast growth factor-2. Developmental dynamics : an official publication of the American Association of Anatomists 238:351–357

    Article  CAS  Google Scholar 

  • Brewer JR, Mazot P, Soriano P (2016) Genetic insights into the mechanisms of Fgf signaling. Genes Dev 30:751–771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet (London, England) 391:572–580

    Article  Google Scholar 

  • Cross MJ, Lu L, Magnusson P, Nyqvist D, Holmqvist K, Welsh M, Claesson-Welsh L (2002) The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. Mol Biol Cell 13:2881–2893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • deAlmeida AC, van Oort RJ, Wehrens XH (2010) Transverse aortic constriction in mice. Journal of visualized experiments : JoVE

  • Doble BW, Dang X, Ping P, Fandrich RR, Nickel BE, Jin Y, Cattini PA, Kardami E (2004) Phosphorylation of serine 262 in the gap junction protein connexin-43 regulates DNA synthesis in cell-cell contact forming cardiomyocytes. J Cell Sci 117:507–514

    Article  CAS  PubMed  Google Scholar 

  • Doble BW, Ping P, Kardami E (2000) The epsilon subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation. Circ Res 86:293–301

    Article  CAS  PubMed  Google Scholar 

  • Florkiewicz RZ, Sommer A (1989) Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci U S A 86:3978–3981

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Frohlich ED, Susic D (2012) Pressure overload. Heart Fail Clin 8:21–32

    Article  PubMed  Google Scholar 

  • Ghosh R, Gilda JE, Gomes AV (2014) The necessity of and strategies for improving confidence in the accuracy of western blots. Expert Rev Proteomics 11:549–560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hirst CJ, Herlyn M, Cattini PA, Kardami E (2003) High levels of CUG-initiated FGF-2 expression cause chromatin compaction, decreased cardiomyocyte mitosis, and cell death. Mol Cell Biochem 246:111–116

    Article  CAS  PubMed  Google Scholar 

  • Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007–2018

    Article  PubMed  Google Scholar 

  • Jhanwar-Uniyal M, Wainwright JV, Mohan AL, Tobias ME, Murali R, Gandhi CD, Schmidt MH (2019) Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv Biol Regul 72:51–62

    Article  CAS  PubMed  Google Scholar 

  • Jiang ZS, Jeyaraman M, Wen GB, Fandrich RR, Dixon IM, Cattini PA, Kardami E (2007) High- but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. J Mol Cell Cardiol 42:222–233

    Article  CAS  PubMed  Google Scholar 

  • Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, Hao J, Cattini PA, Dixon IM, Kardami E (2002) Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 282:H1071-1080

    Article  CAS  PubMed  Google Scholar 

  • Jimenez SK, Jassal DS, Kardami E, Cattini PA (2011) A single bout of exercise promotes sustained left ventricular function improvement after isoproterenol-induced injury in mice. J Physiol Sci : JPS 61:331–336

    Article  CAS  PubMed  Google Scholar 

  • Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK, Cattini PA (2007) Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 12:267–277

    Article  CAS  PubMed  Google Scholar 

  • Khanam SS, Son JW, Lee JW, Youn YJ, Yoon J, Lee SH, Kim JY, Ahn SG, Ahn MS, Yoo BS (2017) Prognostic value of short-term follow-up BNP in hospitalized patients with heart failure. BMC Cardiovasc Disord 17:215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kole D, Grella A, Dolivo D, Shumaker L, Hermans W, Dominko T (2017) High molecular weight FGF2 isoforms demonstrate canonical receptor-mediated activity and support human embryonic stem cell self-renewal. Stem Cell Res 21:106–116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Koleini N, Kardami E (2017) Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 8:46663–46680

    Article  PubMed  PubMed Central  Google Scholar 

  • Koleini N, Nickel BE, Nagalingam RS, Landry NM, Fandrich RR, Dixon IM, Czubryt M, Cattini PA, Kardami E (2019a) Abstract 838: high molecular weight FGF2 contributes to pressure overload induced systolic dysfunction by a mechanism associated with modulation of the NR1D1 orphan nuclear receptor expression. Circ Res 125:A838–A838

    Article  Google Scholar 

  • Koleini N, Nickel BE, Wang J, Roveimiab Z, Fandrich RR, Kirshenbaum LA, Cattini PA, Kardami E (2017) Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway. Oncotarget 8:87415–87430

    Article  PubMed  PubMed Central  Google Scholar 

  • Koleini N, Santiago JJ, Nickel BE, Sequiera GL, Wang J, Fandrich RR, Jassal DS, Dhingra S, Kirshenbaum LA, Cattini PA, Kardami E (2019b) Elimination or neutralization of endogenous high-molecular-weight FGF2 mitigates doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 316:H279-h288

    Article  CAS  PubMed  Google Scholar 

  • Lau AF, Hatch-Pigott V, Crow DS (1991) Evidence that heart connexin43 is a phosphoprotein. J Mol Cell Cardiol 23:659–663

    Article  CAS  PubMed  Google Scholar 

  • Leong DP, McMurray JJV, Joseph PG, Yusuf S (2019) From ACE Inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (Part 2/5). J Am Coll Cardiol 74:683–698

    Article  CAS  PubMed  Google Scholar 

  • Liao S, Bodmer J, Pietras D, Azhar M, Doetschman T, Schultz Jel J (2009) Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease. Developmental dynamics : an official publication of the American Association of Anatomists 238:249–264

    Article  CAS  Google Scholar 

  • Liao S, Bodmer JR, Azhar M, Newman G, Coffin JD, Doetschman T, Schultz Jel J (2010) The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury. J Mol Cell Cardiol 48:1245–1254

    Article  CAS  PubMed  Google Scholar 

  • Liao S, Porter D, Scott A, Newman G, Doetschman T, Schultz Jel J (2007) The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. J Mol Cell Cardiol 42:106–120

    Article  CAS  PubMed  Google Scholar 

  • Liu GY, Sabatini DM (2020) mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 21:183–203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu L, Pasumarthi KB, Padua RR, Massaeli H, Fandrich RR, Pierce GN, Cattini PA, Kardami E (1995) Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. Am J Physiol 268:H1927-1938

    Article  CAS  PubMed  Google Scholar 

  • Lyon RC, Zanella F, Omens JH, Sheikh F (2015) Mechanotransduction in cardiac hypertrophy and failure. Circ Res 116:1462–1476

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ma X, Dang X, Claus P, Hirst C, Fandrich RR, Jin Y, Grothe C, Kirshenbaum LA, Cattini PA, Kardami E (2007) Chromatin compaction and cell death by high molecular weight FGF-2 depend on its nuclear localization, intracrine ERK activation, and engagement of mitochondria. J Cell Physiol 213:690–698

    Article  CAS  PubMed  Google Scholar 

  • Messerli FH, Rimoldi SF, Bangalore S (2017) The transition from hypertension to heart failure: contemporary update. JACC Heart Fail 5:543–551

    Article  PubMed  Google Scholar 

  • Nusayr E, Sadideen DT, Doetschman T (2013) FGF2 modulates cardiac remodeling in an isoform- and sex-specific manner. Physiol Rep 1:

  • Ornitz DM, Itoh N (2015) The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4:215–266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pourcet B, Zecchin M, Ferri L, Beauchamp J, Sitaula S, Billon C, Delhaye S, Vanhoutte J, Mayeuf-Louchart A, Thorel Q, Haas JT, Eeckhoute J, Dombrowicz D, Duhem C, Boulinguiez A, Lancel S, Sebti Y, Burris TP, Staels B, Duez HM (2018) Nuclear receptor subfamily 1 group D member 1 regulates circadian activity of NLRP3 inflammasome to reduce the severity of fulminant hepatitis in mice. Gastroenterology 154:1449-1464.e1420

    Article  CAS  PubMed  Google Scholar 

  • Qu J, Volpicelli FM, Garcia LI, Sandeep N, Zhang J, Marquez-Rosado L, Lampe PD, Fishman GI (2009) Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ Res 104:365–371

    Article  CAS  PubMed  Google Scholar 

  • Reitz CJ, Alibhai FJ, Khatua TN, Rasouli M, Bridle BW, Burris TP, Martino TA (2019) SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome. Commun Biol 2:353

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Santiago JJ, Ma X, McNaughton LJ, Nickel BE, Bestvater BP, Yu L, Fandrich RR, Netticadan T, Kardami E (2011) Preferential accumulation and export of high molecular weight FGF-2 by rat cardiac non-myocytes. Cardiovasc Res 89:139–147

    Article  CAS  PubMed  Google Scholar 

  • Santiago JJ, McNaughton LJ, Koleini N, Ma X, Bestvater B, Nickel BE, Fandrich RR, Wigle JT, Freed DH, Arora RC, Kardami E (2014) High molecular weight fibroblast growth factor-2 in the human heart is a potential target for prevention of cardiac remodeling. PLoS ONE 9:e97281

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Schipke J, Brandenberger C, Rajces A, Manninger M, Alogna A, Post H (1985) Mühlfeld C (2017) Assessment of cardiac fibrosis: a morphometric method comparison for collagen quantification. J Appl Physiol 122:1019–1030

    Article  CAS  Google Scholar 

  • Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, Pagano F, Schiavon S, Bordin A, Carrizzo A, Vecchione C, Valenti V, Chimenti I, De Falco E, Sciarretta S, Frati G (2017) A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev 2017:3920195

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Shan H, Wei J, Zhang M, Lin L, Yan R, Zhang R, Zhu YH (2015) Suppression of PKCε-mediated mitochondrial connexin 43 phosphorylation at serine 368 is involved in myocardial mitochondrial dysfunction in a rat model of dilated cardiomyopathy. Mol Med Rep 11:4720–4726

    Article  CAS  PubMed  Google Scholar 

  • Sheikh F, Fandrich RR, Kardami E, Cattini PA (1999) Overexpression of long or short FGFR-1 results in FGF-2-mediated proliferation in neonatal cardiac myocyte cultures. Cardiovasc Res 42:696–705

    Article  CAS  PubMed  Google Scholar 

  • Shende P, Xu L, Morandi C, Pentassuglia L, Heim P, Lebboukh S, Berthonneche C, Pedrazzini T, Kaufmann BA, Hall MN, Rüegg MA, Brink M (2016) Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy. Cardiovasc Res 109:103–114

    Article  CAS  PubMed  Google Scholar 

  • Srisakuldee W, Jeyaraman MM, Nickel BE, Tanguy S, Jiang ZS, Kardami E (2009) Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc Res 83:672–681

    Article  CAS  PubMed  Google Scholar 

  • Srisakuldee W, Makazan Z, Nickel BE, Zhang F, Thliveris JA, Pasumarthi KB, Kardami E (2014) The FGF-2-triggered protection of cardiac subsarcolemmal mitochondria from calcium overload is mitochondrial connexin 43-dependent. Cardiovasc Res 103:72–80

    Article  CAS  PubMed  Google Scholar 

  • Stujanna EN, Murakoshi N, Tajiri K, Xu D, Kimura T, Qin R, Feng D, Yonebayashi S, Ogura Y, Yamagami F, Sato A, Nogami A, Aonuma K (2017) Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism. PLoS ONE 12:e0189330

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tanai E, Frantz S (2015) Pathophysiology of heart failure. Comprehensive. Physiology 6:187–214

    Google Scholar 

  • Teiger E, Than VD, Richard L, Wisnewsky C, Tea BS, Gaboury L, Tremblay J, Schwartz K, Hamet P (1996) Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 97:2891–2897

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vaissiere A, Berger S, Harrus D, Dacquet C, Le Maire A, Boutin JA, Ferry G, Royer CA (2015) Molecular mechanisms of transcriptional control by Rev-erbalpha: an energetic foundation for reconciling structure and binding with biological function. Protein science : a publication of the Protein Society 24:1129–1146

    Article  CAS  Google Scholar 

  • Volterrani M, Iellamo F, Senni M, Piepoli MF (2017) Therapeutic options of angiotensin receptor neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: beyond RAAS and sympathetic nervous system inhibition. Int J Cardiol 226:132–135

    Article  PubMed  Google Scholar 

  • Walker JR, Sharma A, Lytwyn M, Bohonis S, Thliveris J, Singal PK, Jassal DS (2011) The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 24:699–705

    Article  Google Scholar 

  • Wang F, Iskra B, Kleinerman E, Alvarez-Florez C, Andrews T, Shaw A, Chandra J, Schadler K, Aune GJ (2018) Aerobic exercise during early murine doxorubicin exposure mitigates cardiac toxicity. J Pediatr Hematol Oncol 40:208–215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, Hesselink MK, Paquet C, Delhaye S, Shin Y, Kamenecka TM, Schaart G, Lefebvre P, Neviere R, Burris TP, Schrauwen P, Staels B, Duez H (2013) Rev-erb-alpha modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med 19:1039–1046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang L, Parry GC, Levin EG (2013) Inhibition of tumor cell migration by LD22-4, an N-terminal fragment of 24-kDa FGF2, is mediated by Neuropilin 1. Cancer Res 73:3316–3325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang L, Zhang R, Tien CL, Chan RE, Sugi K, Fu C, Griffin AC, Shen Y, Burris TP, Liao X, Jain MK (2017) REV-ERBalpha ameliorates heart failure through transcription repression. JCI Insight 2:

  • Zhao XS, Pan W, Bekeredjian R, Shohet RV (2006) Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114:830–837

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Research was funded by an operating grant by the Canadian Institutes for Health Research (CIHR, #74733) to Elissavet Kardami (Prinicipall Investigator; with co-applicants Peter Cattini and Davinder Jassal), and by the Molson Women’s Heart Health Foundation (Elissavet Kardami). Other funding: MPC was supported by a CIHR Open Operating Grant (MOP136862). NK and RSN were the recipients of a Bank of Montreal studentship award via the St. Boniface Hospital Albrechtsen Research Centre; NK was also supported via University of Manitoba funding to PAC, who holds the H.G. Friesen Chair in Metabolic and Endocrine Disorders.

Author information

Authors and Affiliations

  1. Departments of Physiology and Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada

    Navid Koleini, Raghu S. Nagalingam, Natalie M. Landry, Ian M. Dixon, Michael P. Czubryt, Davinder S. Jassal & Peter A. Cattini

  2. St. Boniface Hospital Albrechtsen Research Centre, Institute of Cardiovascular Sciences, Winnipeg, Canada

    Navid Koleini, Barbara E. Nickel, Raghu S. Nagalingam, Natalie M. Landry, Robert R. Fandrich, David Y. C. Cheung, Ian M. Dixon, Michael P. Czubryt, Davinder S. Jassal & Elissavet Kardami

  3. Departments of Human Anatomy and Cell Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada

    Robert R. Fandrich & Elissavet Kardami

  4. Departments of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada

    Davinder S. Jassal

  5. Departments of Radiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada

    Davinder S. Jassal

Authors
  1. Navid Koleini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara E. Nickel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raghu S. Nagalingam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natalie M. Landry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert R. Fandrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Y. C. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ian M. Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael P. Czubryt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Davinder S. Jassal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Peter A. Cattini
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Elissavet Kardami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Navid Koleini or Elissavet Kardami.

Ethics declarations

Ethics approval and consent to participate

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

441_2021_3465_MOESM1_ESM.tiff

Supplementary file1 Figure S1. Elimination of Hi-FGF2 prevents pressure overload-induced increase in left ventricular end diastolic diameter (LVESD), but has not effect on left ventricular end diastolic diameter (LVEDD)The graphs show echocardiographic measurements of LVESD, and LVEDD, at 8 weeks post-sham (green) or –TAC surgery (magenta) surgery, in FGF2(WT) and FGF2(Lo) mice, as indicated. Brackets point to significant difference between mice subjected to TAC versus sham surgery (p < 0.05) by 2-way-ANOVA LSD post-hoc. Sample sizes are n = 9–17. (TIFF 8671 KB)

441_2021_3465_MOESM2_ESM.tiff

Supplementary file2 Figure S2. Elimination of endogenous Hi-FGF2 prevents TAC surgery induced increases in cardiomyocyte surface area. Typical picrosirius-red stained images (rendered in black and white) of cardiac transverse sections obtained at 8 weeks post- sham or TAC surgery from FGF2(WT) and FGF2(Lo) groups, as indicated (TIFF 8671 KB)

441_2021_3465_MOESM3_ESM.tiff

Supplementary file3 Figure S3. Typical images of cross-sections from hearts of FGF2(WT) and FGF2(Lo) mice subjected to sham or TAC surgery as indicated. Sections were stained by immunofluorescence for collagen IV, to outline pericellular areas. Typical whole hearts images, placed on an actual ruler (marking 1 mm-distanced segments) are included in each panel (TIFF 8671 KB)

441_2021_3465_MOESM4_ESM.tiff

Supplementary file4 Figure S4. FGFR1 accumulation remains unchanged by FGF2 isoform composition or TAC surgery. Panel a. FGF1 mRNA levels determined by qPCR and normalized to the value for WT-FGF2(Sham) arbitrarily defined as 1. Differences between groups were not statistically significant (P > 0.05), as compared by 2-way ANOVA. Panel b. Relative levels of immunoreactive, ~ 100 kDa, FGFR1, adjusted for variation in protein loading (Ponceau), did not show statistically significant differences between groups. Panel c shows the immunoblot for FGFR1, and the corresponding Ponceau-stained membrane, as indicated. Values from the lane marked with a red asterisk were excluded, due to abnormal appearance of the total protein profile indicative of degradation (TIFF 8671 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koleini, N., Nickel, B.E., Nagalingam, R.S. et al. Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression. Cell Tissue Res 385, 753–768 (2021). https://doi.org/10.1007/s00441-021-03465-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00441-021-03465-0

Keywords

Search

Navigation